Antibody Cocktail Found Effective as a Passive COVID-19 Vaccine

New York-based Regeneron Pharmaceuticals announced positive initial results from an ongoing Phase 3 clinical trial evaluating REGEN-COV™ (casirivimab and imdevimab antibody cocktail) used as a passive vaccine for the prevention of COVID-19 in people at high risk of infection.

"In this prevention trial, REGEN-COV was given as injections rather than an infusion, which makes administration much more convenient and efficient for patients and overburdened healthcare providers and facilities," said David Weinreich, M.D., Executive Vice President and Head of Global Clinical Development at Regeneron, in a press statement.

"It's notable that the few infections that did occur after receiving REGEN-COV were all asymptomatic, and associated with markedly lower viral load and duration of viral shedding, potentially further reducing transmission."

The development and manufacturing of REGEN-COV has been funded in part by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services